Učitavanje...
The molecular targets of approved treatments for pulmonary arterial hypertension
Until recently, three classes of medical therapy were available for the treatment of pulmonary arterial hypertension (PAH)—prostanoids, endothelin receptor antagonists and phosphodiesterase type 5 (PDE5) inhibitors. With the approval of the soluble guanylate cyclase stimulator riociguat, an addition...
Spremljeno u:
| Izdano u: | Thorax |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BMJ Publishing Group
2016
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4717417/ https://ncbi.nlm.nih.gov/pubmed/26219978 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/thoraxjnl-2015-207170 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|